Plasma Proteins Innovation Platform
As a company driven by its promise to patients, we are excited about our further collaboration with PreviPharma, which seeks to identify new plasma proteins for the treatment of diseases with high unmet medical need.
Hematology, infectious disease, gastrointestinal indications, neurology, and inflammation diseases.
- Infection prevention
- Microbial diagnostics
- Antimicrobial stewardship
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
- Market entry
- Marketed product
- Joint Venture
Infectious disease area:
Possible for sharing mutual goals of providing high tech to reduce antibiotic dosages.
We are a small company located in Mannheim that aims for the treatment of diseases with high unmet medical need.
PreviPharma’s MIP program is a convincing approach in addressing unmet medical need and bears an impressive opportunity on finding new paths combating AMR.